Bumetanide blocks CFTR GCl in the native sweat duct

Bumetanide is wellknown for its ability to inhibit the nonconductiveNa⁺-K⁺-2Clcotransporter. We were surprised in preliminary studies to find thatbumetanide in the contraluminal bath also inhibited NaCl absorption inthe human sweat duct, which is apparently poor in cotransporteractivity. Inhibition was accompanied by a marked decrease in thetransepithelial electrical conductance. Because the cystic fibrosistransmembrane conductance regulator (CFTR) Cl channel is richlyexpressed in the sweat duct, we asked whether bumetanide acts byblocking this anion channel. We found that bumetanide1) significantly increased wholecell input impedance, 2)hyperpolarized transepithelial and basolateral membrane potentials, 3) depolarized apical membranepotential, 4) increased the ratio ofapical-to-basolateral membrane resistance, and5) decreased transepithelialCl conductance(G_Cl).These results indicate that bumetanide inhibits CFTRG_Clin both cell membranes of this epithelium. We excluded bumetanideinterference with the protein kinase A phosphorylation activationprocess by "irreversibly" phosphorylating CFTR by usingadenosine5'-O-(3-thiotriphosphate) in thepresence of a phosphatase inhibition cocktail] before bumetanideapplication. We then activated CFTRG_Clby adding 5 mM ATP. Bumetanide in the cytoplasmic bath(10³ M) inhibited ~71%of this ATP-activated CFTRG_Cl,indicating possible direct inhibition of CFTRG_Cl.We conclude that bumetanide inhibits CFTRG_Clin apical and basolateral membranes independent of phosphorylation. Theresults also suggest that>10⁵ M bumetanide cannotbe used to specifically block theNa⁺-K⁺-2Cl cotransporter.